TickerFacts.

Company research / LGND

Ligand Pharmaceuticals Inc (LGND)

Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

SEC name LIGAND PHARMACEUTICALS INC · CIK 0000886163 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Ligand Pharmaceuticals Inc reported revenue of $268.09M. Revenue grew 60.4% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $290.54M.

Key ratios (year ended 2025-12-31)

15.3%
Operating margin
46.4%
Net margin
12.2%
Return on year-end equity
60.4%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$290.54M$268.09M$167.13M$131.31M$196.25M$241.54M$163.56M$120.28M$251.45M$141.10M$108.97M
Cost of Revenuen/an/an/an/an/an/an/an/a$6.34M$5.37M$5.57M
Gross Profit (computed)n/an/an/an/an/an/an/an/an/an/a$103.40M
R&D Expense$41.35M$81.18M$21.43M$24.54M$36.08M$32.10M$40.50M$55.91M$27.86M$26.89M$21.22M
Operating Income$94.73M$41.00M-$22.61M$11.94M$3.04M$103.85M$37.50M$807.08M$163.73M$68.08M$43.88M
Depreciation & Amortization$32.91M$33.77M$35.24M$36.52M$51.53M$51.07M$25.69M$18.36M$12.78M$10.96M$11.29M
EBITDA$127.65M$74.78M$12.63M$48.46M$54.57M$154.92M$63.19M$825.44M$176.51M$79.03M$55.17M
Net Income$197.22M$124.45M-$4.03M$52.15M-$33.36M$57.14M-$2.98M$629.30M$143.32M$12.56M-$1.64M
EPS (Diluted)n/a$6.13-$0.22$2.94-$1.98$3.31-$0.18$31.85$5.96$0.53-$0.08
Total Assets$2.19B$1.56B$941.77M$787.22M$762.67M$1.30B$1.36B$1.49B$1.26B$671.02M$601.59M
Total Liabilities$1.22B$543.42M$111.33M$86.30M$165.18M$476.43M$652.76M$727.68M$699.89M$252.37M$230.73M
Shareholders' Equity$967.52M$1.02B$830.44M$700.91M$597.49M$821.16M$709.52M$767.23M$560.91M$399.79M$341.29M
Cash & Equivalents$1.01B$174.93M$72.31M$22.95M$45.01M$19.52M$47.62M$71.54M$117.16M$20.62M$18.75M
Operating Cash Flow$131.71M$49.36M$97.05M$49.58M$137.85M$78.80M$54.59M-$29.34M$194.06M$88.57M$60.73M
Capital Expenditures$278.0K$452.0K$1.82M$3.52M$17.92M$8.76M$4.46M$2.55M$887.0K$2.16M$1.85M
Free Cash Flow$131.44M$48.91M$95.23M$46.06M$119.93M$70.04M$50.13M-$31.89M$193.17M$86.41M$58.88M
Share Repurchases$75.00M$15.00M$0$0$0$0$78.00M$453.05M$122.87M$1.97M$3.90M
Shares Outstanding19.92M19.77M19.11M17.56M16.95M16.77M16.08M16.82M20.77M21.15M20.91M
Weighted Average Diluted Sharesn/a20.29M18.29M17.76M16.87M17.25M16.82M19.76M24.07M23.48M20.83M
EPS (Basic)n/a$6.44-$0.22$3.02-$1.98$3.44-$0.18$33.13$6.77$0.60-$0.08

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView